Replies to post #134723 on Biotech Values

[acgood]

I don't know if or when it will change, but RNAi technology is not being valued hardly at all anymore (pharma went down that road once). It is more likely that market will start to value RNAi-based drugs with actual clinical data, particularly (IMO) in the current rare diseases "rally"